BCG044 / Biocytogen - LARVOL DELTA

Preclinical study of BCG044, a novel bispecific ADC targeting EpCAM and HER3 for the treatment of colorectal and other tumors (AACR 2026) - "The surrogate ADC demonstrated better tolerance compared to both the parent EpCAM ADC. In summary, BCG044 exhibited the potential to enhance tumor selectivity while maintaining potent efficacy against colorectal and other solid tumors."

ADC • Bispecific • Preclinical • Breast Cancer • Colorectal Cancer • Gastrointestinal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Solid Tumor • ERBB3 • TOP1